Current status and future directions of anti-angiogenic therapy for gliomas.
Heidelberg, Germany. In Neuro Oncol, Nov 2015
UNASSIGNED: Molecular targets for the pathological vasculature are the vascular endothelial growth factor (VEGF)/VEGF receptor axis, integrins, angiopoietins, and platelet-derived growth factor receptor (PDGFR), as well as several intracellular or downstream effectors like protein kinase C beta and mammalian target of rapamycin (mTOR).
Spatiotemporal regulation of PKC via interactions with AKAP7 isoforms.
Farmington, United States. In Biochem J, 2012
Data from studies using recombinant proteins suggest that isoforms of PRKA (A kinase anchor protein 7) exhibit high-affinity interactions with isoforms of PKC (primarily PKCalpha and PKCbeta used here); AKAP7 could dictate PKC localization/function.
Painful diabetic neuropathy: an update.
Chandīgarh, India. In Ann Neurosci, 2011
The newer therapies under studies are NMDA antagonists, aldose reductase inhibitors, neurotropic factors, vascular endothelial growth factor, Gamma linolenic acid, protein kinase C beta inhibitors, immune therapy, hyperbaric oxygen and alpha lipoic acid.
Recent advances in the management of diabetic distal symmetrical polyneuropathy.
Sheffield, United Kingdom. In J Diabetes Investig, 2011
Studies in experimental diabetes examining the pathogenesis of DPN have identified a number of metabolic abnormalities including polyol pathway hyperactivity, increased advanced glycation end-point formation, alterations in the protein kinase C beta pathway through diacylglycerol and oxidative stress.